Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
NCT02325791 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
- Lead sponsor
- Regeneron Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 21, 2015
- Completion date
- September 26, 2017
- Enrollment
- 1,177 (actual)
- Sites
- 205
Conditions
As the registry lists them; a condition with its own page is linked.